Libtayo Gains Approval for First-Line NSCLC With Chemotherapy
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.